Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 1/2017

Open Access 01-01-2017 | Review

Unproven Therapies for Diabetes and Their Implications

Authors: Jothydev Kesavadev, Banshi Saboo, Shaukat Sadikot, Ashok Kumar Das, Shashank Joshi, Rajeev Chawla, Hemant Thacker, Arun Shankar, Lakshmy Ramachandran, Sanjay Kalra

Published in: Advances in Therapy | Issue 1/2017

Login to get access

Abstract

Diabetes is a chronic disease and is one of the leading causes of morbidity and mortality worldwide. Being an ancient disease, many individuals follow complementary and alternative medicinal (CAM) therapies for either the cure or prevention of the disease. The popularity of these practices among the general public is in no way a testimony to their safety and efficacy. Due to the possibility of undesirable interactions with conventional medicines, it is imperative that patients are asked about CAM use during patient assessment. Patient- and physician-targeted awareness programs on various aspects of CAM use must be initiated to create a better understanding of evidence-based use of these practices. In addition, there should be guidelines in place based on clinical trial outcomes, and stricter regulations need to be enforced on CAM practices to ensure their safety and effectiveness.
Literature
1.
Global report on diabetes. Geneva: World Health Organization; 2016.
2.
IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2015.
3.
4.
Life expectancy increased by 5 years since 2000, but health inequalities persist. Geneva: World Health Organization, Observatory GH; 2016 19 May 2016 Report No.
5.
6.
Kesavadev J, Short K, Nair KS. Diabetes in old age: an emerging epidemic. J Assoc Physicians India. 2003;51:1083–94.PubMed
7.
Ebbell B. The Papyrus Ebers, the Greatest Egyptian Medical Document. Copenhagen; Oxford University Press: London; 1937.
8.
9.
Papaspyros NS. The history of diabetes mellitus. 2nd ed. G. Thieme; 1964. p. 213.
10.
Sanders LJ. From Thebes to Toronto and the 21st century: an incredible journey. Diabetes Spectr. 2002;15(1):56–60.CrossRef
11.
Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002;23(4):373–8.PubMed
12.
Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254–64 [Epub 2008/09/20].PubMedPubMedCentralCrossRef
13.
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88 [Epub 2013/01/11].PubMedCrossRef
14.
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9.PubMedCrossRef
15.
Nouwen A, Nefs G, Caramlau I, et al. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care. 2011;34(3):752–62 [Epub 2011/03/02].PubMedPubMedCentralCrossRef
16.
Adeniyi AF, Adeleye JO, Adeniyi CY. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Curr Diabetes Rev. 2010;6(4):201–6.PubMedCrossRef
17.
Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complicat. 2011;25(2):129–36.PubMedCrossRef
18.
19.
Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National Health Stat Rep. 2015;79:1.
20.
Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4–17 years in the United States: National Health Interview Survey, 2007–2012. National Health Stat Rep. 2015;78:1.
21.
Koren R, Lerner A, Tirosh A, et al. The use of complementary and alternative medicine in hospitalized patients with type 2 diabetes mellitus in Israel. J Alternat Complement Med. 2015;21(7):395–400.CrossRef
22.
Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279(19):1548–53.PubMedCrossRef
23.
Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Semin Integr Med. 2004;2(2):54–71.CrossRef
24.
Naja F, Mousa D, Alameddine M, Shoaib H, Itani L, Mourad Y. Prevalence and correlates of complementary and alternative medicine use among diabetic patients in Beirut, Lebanon: a cross-sectional study. BMC Complement Alternat Med. 2014;14(1):1.CrossRef
25.
Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.PubMedCrossRef
26.
Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002;25(2):324–9.PubMedCrossRef
27.
H-Y Chang, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people living with diabetes: literature review. J Adv Nurs. 2007;58(4):307–19.CrossRef
28.
Birdee GS, Yeh G. Complementary and alternative medicine therapies for diabetes: a clinical review. Clin Diabetes. 2010;28(4):147–55.CrossRef
29.
Chacko E. Culture and therapy: complementary strategies for the treatment of type-2 diabetes in an urban setting in Kerala, India. Soc Sci Med. 2003;56(5):1087–98.PubMedCrossRef
30.
American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80 [Epub 2013/12/21].CrossRef
31.
Grant SJ, Bensoussan A, Chang D, et al. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2009;4(4):CD006690. doi:10.​1002/​14651858.​CD006690.​pub2.
32.
33.
Bauml JM, Chokshi S, Schapira MM, et al. Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey. Cancer. 2015;121(14):2431–8.PubMedCrossRef
34.
Kim SH, Shin DW, Nam Y-S, et al. Expected and perceived efficacy of complementary and alternative medicine: a comparison views of patients with cancer and oncologists. Complement Ther Med. 2016;28:29–36.PubMedCrossRef
35.
McCarty RL, Weber WJ, Loots B, et al. Complementary and alternative medicine use and quality of life in pediatric diabetes. J Alternat Complement Med. 2010;16(2):165–73.CrossRef
36.
Spinks J, Johnston D, Hollingsworth B. Complementary and alternative medicine (CAM) use and quality of life in people with type 2 diabetes and/or cardiovascular disease. Complement Ther Med. 2014;22(1):107–15.PubMedCrossRef
37.
Alfian S, Sukandar H, Arisanti N, Abdulah R. Complementary and alternative medicine use decreases adherence to prescribed medication in diabetes patients. Ann Trop Med Public Health. 2016;9(3):174–9.CrossRef
38.
Guthrie D, Guthrie R. Management of diabetes mellitus: a guide to the pattern approach, 6 edn. New York: Springer Publishing Company, LLC; 2008, p 544.
39.
White JR, Jr., Hartman J, Campbell RK. Drug interactions in diabetic patients. The risk of losing glycemic control. Postgrad Med. 1993;93(3):131–2, 5–9 [Epub 1993/02/15].
40.
Niggemann B, Grüber C. Unconventional and conventional medicine: who should learn from whom? Pediatr Allergy Immunol. 2003;14(3):149–55.PubMedCrossRef
41.
Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: part 2: regulatory and safety concerns and proposed governmental policy changes with respect to dietary supplements. Pharm Ther. 2010;35(9):514.
42.
Rehman SU, Choi MS, Choe K, Yoo HH. Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management. Arch Pharm Res. 2015;38(7):1281–98.PubMedCrossRef
43.
Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513–8.PubMedCrossRef
44.
Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutr Metab Cardiovasc Dis. 2005;15(3):149–60.PubMedCrossRef
45.
Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927–41.PubMedCrossRef
46.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs. 2009;69(13):1777–98.PubMedCrossRef
47.
Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement–drug interactions in patients with chronic illnesses. Am Fam Physician. 2008;77(1):73–8.PubMed
48.
Izzo AA. Herb–drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19(1):1–16.PubMedCrossRef
49.
Aslam M, Stockley I. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet. 1979;313(8116):607.CrossRef
50.
Gin H, Orgerie M, Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res. 1989;21(02):81–3.PubMedCrossRef
51.
Neugebauer G, Akpan W, Abshagen U. Interaction of guar with glibenclamide and bezafibrate. Beitr Infusionther Klin Ernahr. 1983;12:40.PubMed
52.
Shane-McWhorter L. Complementary and alternative medicine (CAM) supplement use in people with diabetes: a clinician’s guide. Alexandria, Virginia: American Diabetes Association; 2007.
53.
54.
Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US-and Indian-manufactured ayurvedic medicines sold via the internet. JAMA. 2008;300(8):915–23.PubMedPubMedCentralCrossRef
55.
Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci. 2002;23(3):136–9.PubMedCrossRef
56.
Goudie AM, Kaye JM. Contaminated medication precipitating hypoglycaemia. Med J Aust. 2001;175(5):256.PubMed
57.
Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37(4):344–50.PubMedCrossRef
58.
Ries CA, Sahud MA. Agranulocytosis caused by Chinese herbal medicines: dangers of medications containing aminopyrine and phenylbutazone. JAMA. 1975;231(4):352–5.PubMedCrossRef
59.
Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. Drug Saf. 1997;17(5):342–56.PubMedCrossRef
60.
Lead Poisoning in pregnant women who used ayurvedic medications from India—New York City, 2011–2012. USA: Centers for Disease Control and Prevention; 2012 August 24. Report No.
61.
62.
Keen R, Deacon A, Delves H, Moreton J, Frost P. Indian herbal remedies for diabetes as a cause of lead poisoning. Postgrad Med J. 1994;70(820):113–4.PubMedPubMedCentralCrossRef
63.
Pontifex AH, Garg AK. Lead poisoning from an Asian Indian folk remedy. Can Med Assoc J. 1985;133(12):1227.PubMedCentral
64.
Kulambil Padinjakara RN, Ashawesh K, Butt S, Nair R, Patel V. Herbal remedy for diabetes: two case reports. Exp Clin Endocrinol Diabetes. 2009;117(1):3–5 [Epub 2009/01/14].PubMedCrossRef
65.
66.
Hardy ML, Coulter I, Venuturupalli S, et al. Ayurvedic interventions for diabetes mellitus: a systematic review. Evid Rep Technol Assess (Summ). 2001;(41):2.
67.
Elder C. Ayurveda for diabetes mellitus: a review of the biomedical literature. Altern Ther Health Med. 2004;10(1):44.PubMed
68.
Koh H-L, Woo S-O. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 2000;23(5):351–62.PubMedCrossRef
69.
Cosyns J-P, Jadoul M, Squifflet J-P, Wese F-X, de Strihou CVY. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis. 1999;33(6):1011–7.PubMedCrossRef
70.
Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–92.PubMedCrossRef
71.
72.
73.
Brettel H. Akupunktur als Todesursache. Munch Med Wochenschr. 1981;123(3):97–8.
74.
Mazal DA, King T, Harvey J, Cohen J. Bilateral pneumothorax after acupuncture. N Engl J Med. 1980;302(24):1365.PubMed
75.
Cheng TO. Cardiac tamponade following acupuncture. CHEST J. 2000;118(6):1836–7.CrossRef
76.
Kataoka H. Cardiac tamponade caused by penetration of an acupuncture needle into the right ventricle. J Thorac Cardiovasc Surg. 1997;114(4):674–6.PubMedCrossRef
77.
Kirchgatterer A, Schwarz CD, Holler E, Punzengruber C, Hartl P, Eber B. Cardiac tamponade following acupuncture. CHEST J. 2000;117(5):1510–1.CrossRef
78.
Peuker ET, White A, Ernst E, Pera F, Filler TJ. Traumatic complications of acupuncture: therapists need to know human anatomy. Arch Fam Med. 1999;8(6):553.PubMedCrossRef
79.
Ernst E, White A. Life-threatening adverse reactions after acupuncture? A systematic review. Pain. 1997;71(2):123–6.PubMedCrossRef
80.
Rampes H, James R. Complications of acupuncture. Acupunct Med. 1995;13(1):26–33.CrossRef
81.
82.
Chao Y-FC, Chen S-Y, Lan C, Lai J-S. The cardiorespiratory response and energy expenditure of Tai-Chi-Qui-Gong. Am J Chin Med. 2002;30(04):451–61.
83.
Hagins M, Moore W, Rundle A. Does practicing hatha yoga satisfy recommendations for intensity of physical activity which improves and maintains health and cardiovascular fitness? BMC Complement Alternat Med. 2007;7(1):1.CrossRef
84.
85.
Aljasir B, Bryson M, Al-shehri B. Yoga practice for the management of type II diabetes mellitus in adults: a systematic review. Evid Based Complement Alternat Med. 2010;7(4):399–408.PubMedCrossRef
86.
Innes KE, Vincent HK. The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus: a systematic review. Evid Based Complement Alternat Med. 2007;4(4):469–86 [Epub 2008/01/30].PubMedCrossRef
87.
Lam P, Dennis SM, Diamond TH, Zwar N. Improving glycaemic and BP control in type 2 diabetes: the effectiveness of tai chi. Aust Fam Physician. 2008;37(10):884.PubMed
88.
Lee M, Pittler M, Kim MS, Ernst E. Tai chi for Type 2 diabetes: a systematic review. Diabet Med. 2008;25(2):240–1.PubMedCrossRef
89.
Tsang T, Orr R, Lam P, Comino EJ, Singh MF. Health benefits of Tai Chi for older patients with type 2 diabetes: the “Move It for Diabetes Study”—a randomized controlled trial. Clin Interv Aging. 2007;2(3):429.PubMedPubMedCentral
90.
Tan AC, Mak JC. Complementary and alternative medicine in diabetes (CALMIND)—a prospective study. J Complement Integr Med. 2015;12(1):95–9 [Epub 2015/01/13].PubMed
91.
Ezuruike UF, Prieto JM. The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations. J Ethnopharmacol. 2014;155(2):857–924.PubMedCrossRef
92.
American Diabetes A. Unproven therapies. Diabetes Care. 2004;27(Suppl 1):S135 [Epub 2003/12/25].
93.
Debas HT, Laxminarayan R, Straus SE. Complementary and alternative medicine. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): Oxford University Press, New York; 2006.
94.
Berman JD, Straus SE. Implementing a research agenda for complementary and alternative medicine. Annu Rev Med. 2004;55:239–54.PubMedCrossRef
95.
WHO. Research guidelines for evaluating the safety and efficacy of herbal medicines: Manila: WHO Regional Office for the Western Pacific; 1993.
96.
WHO. Regulatory situation of herbal medicines: a worldwide review. Geneva: World Health Organization; 1998.
97.
Singh A. Regulatory and pharmacological bases of ayurvedic formulations. CRC Press; 2016. 268 p. ISBN 9781498750967.
98.
Misra A, Gulati S, Luthra A. Alternative medicines for diabetes in India: maximum hype, minimum science. Lancet Diabetes Endocrinol. 2016;4(4):302–3.PubMedCrossRef
99.
Mills SY. Regulation in complementary and alternative medicine. Br Med J. 2001;322(7279):158.CrossRef
100.
Bodeker G, Ong CK, Grundy C, Burford G, Shein K. WHO global atlas of traditional, complementary and alternative medicine. Kobe, Japan: WHO Centre for Health Development; 2005.
101.
Ries NM, Fisher KJ. Increasing involvement of physicians in complementary and alternative medicine: Considerations of professional regulation and patient safety. Queen’s Law J. 2013–2014;39(1):273–300.
102.
Drugs and Magic Remedies (Objectionable Advertisements) Act, Stat. 21 (30th April 1954, 1954).
103.
Myers SP, Cheras PA. The other side of the coin: safety of complementary and alternative medicine. Med J Aust. 2004;181(4):222–5.PubMed
104.
Osadebe PO, Odoh EU. Natural products as potential sources of antidiabetic drugs. Br J Pharmaceut Res. 2014;4(17):2075.CrossRef
105.
Oubre A, Carlson T, King S, Reaven G. From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia. 1997;40(5):614–7.PubMedCrossRef
106.
107.
Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–8 [Epub 2004/12/30].PubMedCrossRef
108.
White JR. Apple trees to sodium glucose co-transporter Inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28(1):5–10.CrossRef
109.
Eng J, Kleinman W, Singh L, Singh G, Raufman J-P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–5.PubMed
110.
Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012;59(4):464–71.PubMedCrossRef
111.
Leroux-Stewart J, Rabasa-Lhoret R, Chiasson J-L. α-Glucosidase inhibitors. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM, editors. International textbook of diabetes mellitus. 4th ed. Chichester, UK: Wiley; 2015. p. 673–85. doi:10.​1002/​9781118387658.​ch45.
112.
Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Randomized controlled trials of herbal interventions underreport important details of the intervention. J Clin Epidemiol. 2011;64(7):760–9.PubMedCrossRef
113.
Gagnier JJ, Boon H, Rochon P, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134–49.PubMedCrossRef
114.
Cohen K, Cerone P, Ruggiero R. Complementary/alternative medicine use: responsibilities and implications for pharmacy services. P AND T. 2002;27(9):440–7.
115.
Kwan D, Hirschkorn K, Boon H. US and Canadian pharmacists’ attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review. BMC Complement Alternat Med. 2006;6(1):1.CrossRef
116.
117.
Geil P, Shane-McWhorter L. Dietary supplements in the management of diabetes: potential risks and benefits. J Am Diet Assoc. 2008; 108(4 Suppl 1):S59–65.
118.
DerMarderosian A, Beutler JA. The review of natural products: the most complete source of natural product information. Wolters Kluwer Health; 2010.
119.
Shane-McWhorter L. Biological complementary therapies: a focus on botanical products in diabetes. Diabetes Spect. 2001;14(4):199–208.CrossRef
120.
Smith JD, Clinard VB. Natural products for the management of type 2 diabetes mellitus and comorbid conditions. J Am Pharm Assoc. 2014;54(5):e304–21.CrossRef
121.
Medagama AB, Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? Nutr J. 2014;13:102 [Epub 2014/10/22].PubMedPubMedCentralCrossRef
122.
D’Huyvetter K. Complementary and alternative medicine in diabetes. In: Zazworsky D, Bolin JN, Gaubeca VB, editors. Handbook of diabetes management. Boston, MA: Springer US; 2005. p. 257–71.
Metadata
Title
Unproven Therapies for Diabetes and Their Implications
Authors
Jothydev Kesavadev
Banshi Saboo
Shaukat Sadikot
Ashok Kumar Das
Shashank Joshi
Rajeev Chawla
Hemant Thacker
Arun Shankar
Lakshmy Ramachandran
Sanjay Kalra
Publication date
01-01-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 1/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0439-x

Other articles of this Issue 1/2017

Advances in Therapy 1/2017 Go to the issue

Review

Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview

Original Research

Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts

Original Research

True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Original Research

Efficacy of a Novel Prefilled, Single-Use, Needle-Free Device (Zeneo®) in Achieving Intramuscular Agent Delivery: An Observational Study

Original Research

A Randomized, Clinical Trial to Evaluate Efficacy and Tolerability of Trypsin:Chymotrypsin as Compared to Serratiopeptidase and Trypsin:Bromelain:Rutoside in Wound Management

Original Research

Examining the Impact of Rehospitalization on Healthcare Cost of Myocardial Infarction Patients in Beijing: A Retrospective Observational Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits